FZD7 and ovarian carcinoma: Our group previously showed that FZD7 drives in vitro aggressiveness in ovarian cancer (OC) via the noncanonical Wnt/PCP pathway (Asad et al., 2014) while inhibition of FZD receptors through antibody binding reduced tumor‐initiating cell populations in a range of tumor types (Gurney et al., 2012) making the FZD7 pathway very intriguing and warrants further exploration of its regulatory mechanisms and potential for therapeutic targeting.